AXIM BIOTECHNOLOGIES, INC.
AXIM evidence brief
What we can confirm
- Market Cap:
- $1.4M
What it means
What to watch
Prepared research question
What matters most for AXIM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AXIM
AXIM Biotechnologies, Inc. is an early-stage biotechnology company focused on developing diagnostic and therapeutic products for dry eye disease (DED) and other indications, with no reported revenue and ongoing operating losses as of mid-2024.
Key risk: No revenue and negative equity
Market Cap
$1.4M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2024.
Tracking 1 clinical trial for AXIM BIOTECHNOLOGIES, INC..
AXIM Biotechnologies, Inc. is an early-stage biotechnology company focused on developing diagnostic and therapeutic products for dry eye disease (DED) and other indications, with no reported revenue and ongoing operating losses as of mid-2024.
- AXIM reported total revenue of $0.0M and net income of -$2.3M for the period ended June 30, 2024 [sec].
- Shareholders' equity was -$9.5M as of June 30, 2024, indicating negative net worth [sec].
- The company has an accumulated deficit related to continuing operations, reported as $57,882,227 for 2020 and $41,849,922 for 2019 [sec · filed 2022-04-19].
- AXIM is commercializing a dry eye disease diagnostic technology through a partnership with Versea, aiming to penetrate the ophthalmologist and optometrist marketplace [sec_mda · as of 2022-11-14].
- The company continues to incur significant research and development expenses and expects operating losses to increase as it advances product candidates into further clinical trials [sec · filed 2022-04-19].
What works
- AXIM has a partnership with Versea to commercialize a dry eye disease diagnostic technology, which the company describes as 'industry-changing' [sec_mda · as of 2022-11-14].
- The company has identified potential strategic acquisition targets to accelerate its DED diagnostic and therapeutic applications [sec_mda · as of 2022-11-14].
What to weigh
- AXIM has generated no revenue from product sales and reported a net loss of $2.3M for the six months ended June 30, 2024 [sec].
- Shareholders' equity is deeply negative at -$9.5M as of June 30, 2024, reflecting sustained operating losses and potential insolvency risk [sec].
- The company acknowledges that it is uncertain when, if ever, it will generate revenue from product sales, and that it requires significant additional capital to fund ongoing development [sec · filed 2022-04-19].
- AXIM operates in a highly competitive and rapidly changing industry, and its product candidates require extensive additional research, clinical trials, and regulatory approval before commercialization [sec · filed 2023-06-02].
From the filings
Quoted directly from source documents.
The company had an accumulated deficit of $57.9 million in 2020.
“we had an accumulated deficit related to our continuing operations of $57,882,227”
SEC filings · April 19, 2022
AXIM is commercializing a DED diagnostic through a partnership with Versea.
“With our partnership with Versea, Axim is now commercializing a healthcare solution that holds the potential to truly revolutionize the w”
SEC MD&A · November 14, 2022
Risks & what to watch (4)›
Key risks
- No revenue and negative equity — AXIM has zero revenue and negative shareholders' equity of -$9.5M as of June 30, 2024, indicating severe financial strain [sec].
- Uncertain path to commercialization — The company states it is uncertain when, if ever, it will generate revenue from product sales [sec · filed 2022-04-19].
- Dependence on additional financing — AXIM requires significant additional capital to fund clinical trials and commercialization, and cannot entirely fund these efforts with current resources [sec · filed 2023-06-02].
- Competitive and regulatory risks — The company operates in a dynamic, highly competitive industry and faces risks from technological change, regulatory approval, and dependence on key personnel and third parties [sec · filed 2023-06-02].
What to watch
- Whether AXIM can secure additional financing to continue operations and advance its product candidates [sec · filed 2023-06-02].
- Progress of the Versea partnership in commercializing the DED diagnostic technology and penetrating the ophthalmology market [sec_mda · as of 2022-11-14].
- Any updates on clinical trial initiation for AXIM's product candidates, including SPX-009 and COVID-19 related candidates [sec · filed 2022-04-19].
- Changes in accumulated deficit and cash position in future financial filings, as the company expects operating losses to increase [sec · filed 2022-04-19].
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run AXIM BIOTECHNOLOGIES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AXIM BIOTECHNOLOGIES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Dec 2022Institutional holders
1
Total value held
$0
| Holder | Shares | Value |
|---|---|---|
| massmutual trust co fsb/adv | 500 | $0 |
Frequently asked questions
What is the AI investment thesis for AXIM BIOTECHNOLOGIES, INC.?
AXIM Biotechnologies, Inc. is an early-stage biotechnology company focused on developing diagnostic and therapeutic products for dry eye disease (DED) and other indications, with no reported revenue and ongoing operating losses as of mid-2024.
Who is the CEO of AXIM BIOTECHNOLOGIES, INC.?
Ms. Catalina Valencia J.D. is the chief executive officer of AXIM BIOTECHNOLOGIES, INC. (AXIM).
Where is AXIM BIOTECHNOLOGIES, INC. headquartered?
AXIM BIOTECHNOLOGIES, INC. (AXIM) is headquartered in San Diego, CA, United States.
What therapeutic areas does AXIM BIOTECHNOLOGIES, INC. focus on?
AXIM BIOTECHNOLOGIES, INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.